The staff conducts several clinical research trials studying new treatments for Huntington's disease, Tourette's syndrome and dystonia, and a new treatment using botulinum toxin for migraines. Epilepsy - The CNI Epilepsy Center is known throughout the Rocky Mountain region as a center of excellence for the diagnosis and treatment of epilepsy. Under the leadership of medical director Ronald Kramer, MD, the Epilepsy Center celebrated its 12-year anniversary in 2000. Effective January 2001, Barbara Phillips, MD, is the new medical director of the Epilepsy Center, with Kirsten Bracht, MD, remaining as the co-medical director. This change has allowed Dr. Kramer to become the full-time medical director of the CNI Sleep Disorders Center.
Patients have access to ongoing clinical trials testing new drug treatments and therapies.
If drug therapies are not successful, patients may consider several types of epilepsy surgery, including vagal nerve stimulation. Outcomes analysis helps the staff evaluate and maintain the highest standards of patient satisfaction and quality. By providing patients and their families with the most comprehensive information available, the CNI Epilepsy Center helps them make informed decisions about their options. Medical director David Kelsall, MD, played a pivotol role in clinical trials leading to FDA approval of both the cochlear implant and the Vibrant Sound Bridge implantable hearing aid, and has established CNI as a regional training center in cochlear implant surgery for physicians from across North and South America. As an organizer of the World Hearing Network, Dr. Kelsall leads a team of volunteer doctors and nurses on annual missions to Third World Countries.